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MEMBERSHIP
The ISN provides an international forum for the ex-
change of knowledge, best clinical practice, and research.
Since it was founded in 1960, the Society has constantly
made major contributions to the worldwide advancement
of education, science, and patient care in nephrology.
The ISN’s more than 7000 members include re-
searchers and clinicians from over 100 countries involved
in basic, translational, and applied science. Through this
global network of professionals, the ISN is focused on
designing programs that aim to understand and diagnose
kidney disease and provide suitable treatment, either to
prevent the disease or slow its progression.
Join the ISN today and become a member of the world’s
leading network of nephrologists. Membership includes a
1-year subscription to Kidney International and a number
of other exclusive benefits.
For complete information relating to membership or
any of the ISN’s programs and activities, please visit the
Membership section of the ISN Web site at http://www.
isn-online.org or by contacting the ISN Global Headquar-
ters at Avenue de Tervueven 300, B-1150, Brussels, Bel-
gium. Telephone: +32-2-743 1546; Fax: +32-2-743 1550;
E-mail: info@isn-online.org
MEETING ANNOUNCEMENTS
The Post Satellite Meeting on Hypertension & the
Kidney will be held July 1-3, 2005 at the Esplanade
Hotel in Fremantle, Perth, Western Australia. This
meeting will follow the 3rd World Conference of
Nephrology in Singapore. A forum of internation-
ally renowned speakers will gather in Perth to present
breakthrough topics and debate on controversial is-
sues in hypertension. Registrations open in the mid-
dle of February and we encourage WCN delegates
to take advantage of the Early Bird price savings of
$75 AUD. For further information or to register, con-
tact EventEdge. E-mail: info@eventedge.com.au; Web
site: www.eventedge.com.au/hypertension2005
The 14th International Vicenza Course on Hemodialy-
sis will be held May 24-27, 2005, in Vicenza, Italy. This
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course on hemodialysis is held every three years in strict
collaboration with the industry of the field. A series of lec-
tures and panel discussions wil be held during the days
of the course. Several of the most actual and interest-
ing issues in the field of hemodialysis will be debated
and discussed by world-leading experts. For further in-
formation, contact: Dr. Anna Saccardo, Secretariat of the
14th International Vicenza Course on Hemodialysis, Via
Bertesina, 394, 36100, Vicenza, Italy. Telephone/Fax: +39
444 993949; E-mail: info@vicenzanephrocourses.com
The Sixth International Meeting of the International
Federation of Kidney Foundations (IFK) will be held May
31-June 3, 2005 in Dublin, Ireland. For further informa-
tion, contact: Mr. Mark Murphy, CEO Irish Kidney As-
sociation. Fax: +353-1-837-3974; E-mail: markmurphy@
ika.ie
The XLII ERA-EDTA Congress will be held June 4-7,
2005 in Istanbul, Turkey. For detailed information about
scientific program, registrations, and industrial exhibi-
tion, contact ERA-EDTA Congress Office. Telephone:
+39-0521-98078; Fax: +39-0521-959242; E-mail: congress
@era-edta.org; Web site: www.eraedta2005.org
The 12th International Vasculitis and ANCA Workshop
will be held June 15-18, 2005, at the German Cancer Re-
search Centre, Heidelberg, Germany. The meeting will
focus on the pathogenesis of primary, ANCA-associated
vasculitis, on novel therapeutic approaches, and on the
clinical management of critically ill patients. The regis-
tration deadline is May 1, 2005 at a reduced fee or on-
site. For further information and registration forms, see
http://www.ANCA-heidelberg.de
The 12th Budapest Nephrology School (Nephrology,
Hypertension, Dialysis, Transplantation) will be held
August 25-30, 2005, under the auspices of the ISN,
ERA-EDTA, and EKRA, and organized by the Hun-
garian Kidney Foundation at the Semmelweis Univer-
sity. For further information, contact: La´szlo´ Rosivall,
M.D., Ph.D., D.M.Sc., President, Semmelweis University,
Faculty of Medicine, Department of Pathophysiology,
International Nephrology Research & training Center,
Nagyva´rad te´r 4, l089 Budapest, Hungary. Telephone/Fax:
+36-1-2100-100; E-mail: rosivall@net.sote.hu
The 9th International Conference on Endothelins (ET-
9) will be held September 11-14, 2005, in Park City, Utah.
The conference includes talks and poster sessions ded-
icated to furthering the understanding of the biologic
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and pathologic roles of endothelin. Key topics include
basic synthesis, receptors, signaling, pathways, general
and organ-specific pathogenic mechanisms, and applica-
tion of endothelin antagonists to the treatement of hu-
man disease. For further details, see http://www.int.med.
utah.edu/et9/
Visit http://www.isn-online.org/uploadedfiles/isn/e-
update/ for a complete listing of future meetings
AWARDS AND GRANTS
The Bernd Tersteegen Award 2005
The Bernd Tersteegen Award is intended to bring to
international prominence the theoretic and practical re-
search regarding the insufficiency of kidney function from
a nephrologist’s perspective and especially in the field of
out-patient therapy. Works should be oriented toward
solving problems inherent in this sector, both from a the-
oretic and practical standpoint.
This award (8.000 Euro) is presented annually and
is sponsored by Hoffmann-La Roche AG (Grenzach-
Wyhlen/Germany) for the best evaluated entry. If two or
more entries are considered equal in relevance, the award
may be shared, but the focus is to isolate the single-most
worthy applicant. Applicants should be engaged in any
of the following research endeavors: kidney failure and
out-patient kidney therapy in the clinic, surgery or re-
search physicians in laboratories, scientists or graduated
engineers. Only original scientific theses either published
between 2004 and 2005 or as yet still unpublished are ac-
ceptable and should be submitted in German or English.
Reviews, dissertations, and university lecturing qualifi-
cations are unacceptable, as are works entered in other
competitions. If the participation has been generated by
a working group, only one should be chosen as its rep-
resentative. A current, shortened curriculum vitae and a
listing of publications should be enclosed.
Five copies of the materials should be submitted by July
15, 2005 to Verban Deutsche Nierenzentren der DDnA¨
e. V., Priv. Doz. Dr. med. Werner Kleophas, President,
Postfact 132304, D-42050 Wuppertal. The evaluation will
be made by a jury comprising the managing committee
and members of the Verband Deutsche Nierenzentren
der DDnA¨ e. V. The president of the DDnA¨ is automat-
ically the chairman of the jury.
The presentation of the award will be made during the
annual meeting of the Association on November 19, 2005,
in Mannheim.
BOOKS RECEIVED
Handbook of Kidney Transplantation, Fourth Edition,
edited by Gabriel M. Danovitch. Philadelphia: Lippin-
cott Williams & Wilkins, a Wolters Kluwer Company,
2005. ISBN: 0-7817-5322-8. This 542-page soft cover text
is geared toward “physicans and surgeons entrusted with
the care of transplantation patients, as well as nurses, and
other professionals on the transplantation team.” The
handbook written by 39 experts in the field contains 19
chapters with topics ranging from options for patients
with kidney failure, transplantion immunobiology, histo-
compatibility testing, cross-matching, and allocation of
kidney transplants; immunosuppressive medication and
protocols for kidney transplantation; medical and surgi-
cal aspects of kidney donation, evaluation and prepa-
ration of renal transplant candidates, the transplant
operation and its surgical complications, the first three
transplant months, long-term post transplant manage-
ment and complications, infections in kidney transplanta-
tion, kidney transplantation and liver disease, diagnostic
imaging in kidney transplantation, kidney and pancreas
transplantation in diabetic patients; kidney transplan-
tation in children, psychiatric aspects of kidney trans-
plantation, ethical and legal issues surrounding kidney
transplantation, nutrition in the kidney transplant recip-
ient, to psychosocial and financial aspects of transplanta-
tion. Each chapter includes figures, tables, and relevant
listings to help the reader. In addition, at the end of each
chapter is a listing of selected readings. At the end of the
text is a listing a websites and a comprehensive subject
index. The cost of the text is $49.95.
Medical Management of Kidney Transplantation,
edited by Matthew R. Weir. Philadelphia: Lippincott
Williams & Wilkins, a Wolters Kluwer Company, 2005.
ISBN: 0-7817-4491-1. According to the preface of this
hard-cover text, Dr. Weir states, “Kidney transplant re-
cipients are a unique group of patients who are being
seen more commonly in general medical practices. . . .
The purpose of this book is to provide the reader with a
compendium of the latest advances and understandings
regarding the complex medical problems seen in these
patients.” In addition to Dr. Weir’s contribution, he in-
vited 72 well-known and highly regarded professionals
to provide contributions to this 35-chapter book. These
35 chapters are divided into three separate sections: pre-
transplantation, transplantation, and the longest, post-
transplantation. Each chapter begins with an overview
of the chapter and within the text includes tables, grafts,
and figures that complement the text. Each chapter also
includes a listing of references and a comprehensive sub-
ject index at the end of the text. The cost of this textbook
is $129.00.
Manual of Nephrology, Sixth Edition, edited by Robert
W. Schrier. Philadelphia: Lippincott Williams & Wilkins,
a Wolters Kluwer Company 2005. ISBN: 0-7817-5020-2.
The popularity of this soft-cover manual is reflected in
the fact that is has been revised and updated on six sepa-
rate occasions over the years. The 19 chapters in this new
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edition update all the original material, including the ede-
matous patient, the patient with hyponatremia or hyper-
natremia, the patient with hypokalemia or hyperkalemia,
the patient with an acid-base disorder, the patient with
disorders of serum calcium and phosphate, the patient
with kidney stones, the patient with urinary tract infec-
tion, the patient with hematuria, proteinuria, or both, and
abnormal findings on urinary microscopy, the patient with
acute renal failure, the patient with chronic kidney dis-
ease, the patient with kidney disease and hypertension in
pregnancy, the patient with hypertension, and practical
guidelines for drug dosing in patients with renal impair-
ment, and includes new information on glomerulonephri-
tis and vasculitis and expanded information on dialysis
and kidney transplantation. The actual text uses an out-
line format, which makes this manual very user friendly.
Algorithms for treatment are scattered throughout the
text, as are figures and tables. Each chapter has a listing
of relevant selected readings, and there is a comprehen-
sive subject index. The cost of this manual is $42.95.
Fibrogenesis: Cellular and Molecular Basis, edited
by Mohammed S. Razzaque. New York, Kluwer Aca-
demic/Plenum Publishers, 2005. ISBN: 0-306-47861-7.
This 216-page, 15-chapter hard-bound text, according to
the Preface, “is especially designed to provide integral
and comprehensive information on fibrogenesis.” Top-
ics include tissue scarring, pathological significance of re-
nal expression of proinflammatory molecules, oxidative
stress, lipoproteins, and angiotensin II, involvement of
NF-jB in renal inflammation and sclerosis, low-density
lipoprotein and glomeruloclerosis, molecular develop-
ments in the treatment of renal fibrosis, myocardial
infaction and cardiac fibrogenesis, cardiac fibrosis and
aging, matrix remodeling and atherosclerosis effect of
age, molecular and cellular aspects of liver fibrosis, recent
therapeutic developments in hepatic fibrosis, reversibil-
ity of live fibrosis, the effect of manipulation of apoptotic
cell death and tissue scarring, pulmonary fibrogeneis, and
silica-induced inflammatory mediators and pulmonary fi-
brosis. Each chapter begins with a short abstract and ends
with a complete listing of references. There are many dia-
grams, tables, black and white and color photographs, and
algorithms scattered throughout the text. Finally, there is
a listing of common abbreviations at the beginning and a
comprehensive subject index at the end. The cost of the
text is $139.00.
ERRATA
PETERS M, BIHL GR, BIRD NJ, PETERS C, BRADLEY JR: Radionuclide method for evaluating
the performance of hemodialysis in vivo. Kidney Int 67:721–731, 2005
In the above-mentioned article, on page 731, the following should be added at the end of the text:
ACKNOWLEDGMENTS
The authors are grateful to Professor A. Meyers and Dr. N.A. Hoenich for helpful criticism
and advice. Dr. Geoffrey R. Bihl was supported by The National Kidney Foundation of
South Africa and the Natal KidneyFoundation (South Africa).
The authors apologize for the exclusion.
BARRETO DV, BARRETO FC, CARVALHO AB, CUPPARI L, CENDOROGLO M, DRAIBE SA,
MOYSE´S RMA, NEVES CL, JORGETTI V, BLAIR A, GUIBERTEAU R, CANZIANI ME:
Coronary calcification in hemodialysis patients: The contribution of traditional and
uremia-related risk factors. Kidney Int 67:1576–1582, 2005
In the above-mentioned article, on page 1577, in the right-hand column, under the
heading Imaging Procedure, in the 18th line, the sentence “The total score was the
sum of each coronary score and was expressed modified Agaston et al [11] and
Janowitz et al [12] units” should read
“The total score was the sum of each coronary score and was expressed in modified
Agatston units [11, 12].”
On page 1578, in the left-hand column, under the heading Bone Biopsy, in the second
paragraph, in the 17th line, the word “bellow” should be “below.”
On page 1578, in the right-hand column, Table 1 should read as follows:
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Table 1. Demographic, clinical and laboratorial characteristics of the patients (N = 101)
Age years 48 ± 13 (21–81)
Gender female/male 67/34
Race white/nonwhite 57/44
Etiology of end-stage renal disease
Unknown % 28
Hypertension % 27
Chronic glomerulonephritis % 19
Diabetes mellitus % 9
Others % 18
End-stage renal disease diagnosis months 64 ± 65 (6–336)
Length on hemodialysis months 37 ± 25 (4–103)
Body mass index kg/m2 25 ± 4.3 (17.4–36.6)
Comorbid conditions
Hypertension % 70
Diabetes mellitus % 16
Smoking % 25
Hemoglobin g/dL 11.3 ± 1.6 (6.4–15.3)
Kt/V 1.3 ± 0.2 (0.64–1.9)
Cholesterol mg/dL 165.4 ± 41.7 (89–308)
High-density lipoprotein cholesterol mg/dL 42 ± 10.4 (20–71)
Low-density lipoprotein cholesterol mg/dLa 91.3 ± 29.6 (28–161)
Very low-density lipoprotein cholesterol mg/dLa 29.5 ± 15.8 (7–79)
Triglycerides mg/dL 156.5 ± 93.4 (34–489)
Homocysteine mmol/Lb 41 ± 35.1 (10.4–160.2)
Albumin g/dL 3.8 ± 0.2 (3.2–4.5)
C-reactive protein mg/L 9.8 ± 16.3 (0.5–129)
Antioxidized low-density lipoprotein EU/mLc 27.3 ± 22.1 (0–126)
Ionized calcium mmol/L 1.24 ± 0.08 (0.96–1.45)
Phosphorus mg/dL 7.22 ± 1.8 (5.5–19.2)
Alkaline phosphatase U/L 245.3 ± 152.5 (88–1155)
Intact parathyroid hormone pg/mL 351.3 ± 310.1 (9–1266)
25-(OH) vitamin D3 ng/dLc 32.8 ± 14.7 (11.2–94.4)
Osteoprotegerin pg/mLc 174.7 ± 71.7 (42.2–434.8)
sRANK-L pg/mLc 5.4 ± 8.7 (1.5–50.6)
sRANK-L is soluble receptor activator of nuclear factor-jB ligard. Values expressed as mean ± SD (range) and proportions.
aN = 98; bN = 99; cN = 87.
On page 1579, Tables 2, 3, and 4 should read as follows:
Table 2. Histomorphometric characteristics (N = 98)
Trabecular bone volume % 16.6 (6.8–41.3)
Osteoid volume % 2.8 (0.1–18.7)
Osteoid thickness lm 7.65 (2.8–18.5)
Osteoid surface % 21.8 (1.9–71)
Osteoblast surface % 2.75 (0–31.1)
Eroded surface % 4.0 (0–25.3)
Osteoclast surface % 0.7 (0–4)
Trabecular thickness lm 111.8 (77.3–159.7)
Trabecular separation lm 534.25 (197–1526.8)
Trabecular number mm 1.55 (0.6–7.31)
Fibrosis volume % 0.04 (0–2.9)
Mineralizing surface % 2.1 (0–20.6)
Mineral apposition rate l/day 0.70 (0–1.9)
Bone formation rate l3/l2/day 0.02 (0–0.39)
Adjusted apposition rate l/day 0.09 (0–1)
Mineralization lag time days 45.2 (7–494.5)
Values expressed as median (range).






Values expressed as median (range) and proportions.
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Table 4. Coronary calcification correlations
Univariate R P value
Age 0.57 <0.000001
Cardiovascular risk (Framingham) 0.56 <0.000001
Osteoprotegerin 0.44 0.00002
Body mass index 0.24 0.01
Bone volume −0.24 0.02
Trabecular thickness −0.22 0.03
C-reactive protein 0.18 0.062
Multivariate b coefficient P value 95% CI
Osteoprotegerin 7.28 0.00018 3.59–10.99
On page 1579, in left-hand column, the first full paragraph should read:
Total cholesterol levels higher than 200 mg/dL were observed in 17% of the patients, low-density
lipoprotein (LDL) cholesterol >100 mg/dL in 33%, high-density lipoprotein (HDL) cholesterol
<40 mg/dL in 49%, and triglycerides >150 mg/dL in 39% of them. All but one patient had
hyperhomocysteinemia (homocysteine >14 mmol/L). The mean values of CRP and antibody
against oxLDL were increased. CRP >1.1 mg/L was observed in 93% of the patients, and 61%
had CRP >5.0 mg/L. Antibody against oxLDL was positive in 44% of the patients.
On page 1580, in the left-hand column, in the last line, “Hcy,” should read “hyperhomocyteinemia,”
On page 1580, the right-hand column, in the second line, “Hcy” should read “hyperhomocyteinemia”
On page 1581, in the left-hand column, the third full paragraph should read:
Although in this study we did not find any association between the different bone histologic
diagnostic patterns and the extent of coronary artery calcification, when we analyzed each
histomorphometric parameter, we observed that trabecular bone volume and trabecular bone
thickness correlated negatively with coronary calcium score. Previous studies demonstrated the
relationship between reduced bone mass and vascular calcification in the elderly with
osteoporosis and also in hemodialysis patients [22, 40]. London et al [8] observed an association
between low bone activity as well as adynamic bone disease and arterial calcification
evaluated through ultrasonography. In fact, vascular calcification seems to be a process
similar to bone formation that may involve calcium mobilization from bone, excessive
calcium positive balance (from the dialysate fluid and or the calcium-based phosphate binders),
or a bone-buffering capacity insufficient relatively to the amount of calcium load [35, 41, 42].
On page 1581, in the right-hand column, in the first full paragraph, in the 9th line, the word
“osteoporosis” should read “osteopetrosis”
On page 1581, in the right-hand column, in the second full paragraph in the 3rd line, “Hcy”
should be “hyperhomocyteinemia”
Reprint requests to Maria E.F. Canziani, Rua Pedro de Toledo, 232, CEP 04039-000, Sa˜o Paulo-SP, Brazil
E-mail: dialisefor@uol.com.br
The authors and the Editorial Office apologize for the errors.
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